|
顯示項目 414841-414850 / 2348971 (共234898頁)
<< < 41480 41481 41482 41483 41484 41485 41486 41487 41488 41489 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang, Shang-Yi; Lin, Chung-Wu; Lin, Hsiu-Hsia; Yao, Ming; Tang, Jih-Luh; Wu, Shang-Ju; Chen, Yao-Chang; Lu, Hsiao-Yun; Hou, Hsin-An; Chen, Chien-Yuan; Chou, Wen-Chien; Tsay, Woei; Chou, Sheng-Je; Tien, Hwei-Fang; 蔡偉; 林中梧; 姚明; 陳建源; 陳耀昌; 田蕙芬; 陳宜君; 黃聖懿; 吳尚儒; 唐季祿; 周文堅; 侯信安 |
| 臺大學術典藏 |
2018-09-10T14:49:46Z |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang, S.-Y. and Lin, C.-W. and Lin, H.-H. and Yao, M. and Tang, J.-L. and Wu, S.-J. and Chen, Y.-C. and Lu, H.-Y. and Hou, H.-A. and Chen, C.-Y. and Chou, W.-C. and Tsay, W. and Chou, S.-J. and Tien, H.-F.; Huang, Shang-Yi;Lin, Chung-Wu;Lin, Hsiu-Hsia;Yao, Ming;Tang, Jih-Luh;Wu, Shang-Ju;Chen, Yao-Chang;Lu, Hsiao-Yun;Hou, Hsin-An;Chen, Chien-Yuan;Chou, Wen-Chien;Tsay, Woei;Chou, Sheng-Je;Tien, Hwei-Fang; 蔡偉;林中梧;姚明;陳建源;陳耀昌;田蕙芬;陳宜君;黃聖懿;吳尚儒;唐季祿;周文堅;侯信安; 蔡偉;林中梧;姚明;陳建源;陳耀昌;田蕙芬;陳宜君;黃聖懿;吳尚儒;唐季祿;周文堅;侯信安; HWEI-FANG TIEN; Huang, Shang-Yi; Lin, Chung-Wu; WEN-CHIEN CHOU; Lin, Hsiu-Hsia; HSIN-AN HOU; Yao, Ming; CHUNG-WU LIN; Tang, Jih-Luh; JIH-LUH TANG; SHANG-YI HUANG; Wu, Shang-Ju; MING YAO; Chen, Yao-Chang; Lu, Hsiao-Yun; Hou, Hsin-An; Chen, Chien-Yuan; Chou, Wen-Chien; Tsay, Woei; Chou, Sheng-Je; Tien, Hwei-Fang; ???y?g |
| 臺大學術典藏 |
2020-03-03T03:36:44Z |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang S.-Y.; CHUNG-WU LIN; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
HWEI-FANG TIEN; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Lu H.-Y.; Chen Y.-C.; Wu S.-J.; Tang J.-L.; Lin H.-H.; Yao M.; Huang S.-Y.; Lin C.-W. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
MING YAO; Lin C.-W.; Lin H.-H.; Huang S.-Y.; Chou S.-J.; Chou W.-C.; Tsay W.; Chen C.-Y.; Hou H.-A.; Chen Y.-C.; Lu H.-Y.; Wu S.-J.; Tang J.-L.; Tien H.-F. |
| 臺大學術典藏 |
2021-01-06T03:58:33Z |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang S.-Y.; Lin C.-W.; Lin H.-H.; Yao M.; JIH-LUH TANG; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
SHANG-YI HUANG; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2021-02-05T06:29:33Z |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang S.-Y.; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; WEN-CHIEN CHOU; Tsay W.; Chou S.-J.; Tien H.-F. |
| 臺大學術典藏 |
2014 |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Yao M.; Lin H.-H.; Lin C.-W.; Huang S.-Y.; Tien H.-F.; Tang J.-L.; SHANG-JU WU; Chen Y.-C.; Lu H.-Y.; Hou H.-A.; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J. |
| 臺大學術典藏 |
2022-01-12T07:07:33Z |
Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
|
Huang S.-Y.; Lin C.-W.; Lin H.-H.; Yao M.; Tang J.-L.; Wu S.-J.; Chen Y.-C.; Lu H.-Y.; HSIN-AN HOU; Chen C.-Y.; Chou W.-C.; Tsay W.; Chou S.-J.; Tien H.-F. |
顯示項目 414841-414850 / 2348971 (共234898頁)
<< < 41480 41481 41482 41483 41484 41485 41486 41487 41488 41489 > >>
每頁顯示[10|25|50]項目
|
